Dogwood Therapeutics, Inc. (DWTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
44 Milton Avenue
Alpharetta, GA 30009
United States of America (the)
Phone
866 620 8655
Website
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
December 17, 2020
| Name | Title | Pay | Year Born |
| Gregory Duncan | Chairman & Chief Executive Officer | 944,130 | 1965 |
| William L. Pridgen | Founder & Member of Scientific Advisory Board | 16,333 | 1961 |
| Ralph D. Grosswald | Senior Vice President of Operations | 274,693 | 1969 |
| Angela Walsh | Chief Financial Officer, Secretary & Treasurer | 472,909 | 1967 |
| R. Michael Gendreau | Chief Medical Officer | 551,135 | 1956 |
| Carol Duffy | Chief Scientific Advisor | 0 | N/A |
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.